Cargando…

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

Limited data exist regarding treatment patterns and outcomes in elderly patients with HER2-positive metastatic breast cancer (MBC). registHER is an observational study of patients (N = 1,001) with HER2-positive MBC diagnosed within 6 months of enrollment and followed until death, disenrollment, or J...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaufman, Peter A., Brufsky, Adam M., Mayer, Musa, Rugo, Hope S., Tripathy, Debu, Yood, Marianne Ulcickas, Feng, Shibao, Wang, Lisa I., Quah, Cheng S., Yardley, Denise A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2012
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439611/ https://www.ncbi.nlm.nih.gov/pubmed/22923238 http://dx.doi.org/10.1007/s10549-012-2209-z

Ejemplares similares

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

De Novo Versus Recurrent HER2‐Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry
por: Tripathy, Debu, et al.
Publicado: (2019)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer
por: Kaufman, Peter A, et al.
Publicado: (2014)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
por: Tripathy, Debu, et al.
Publicado: (2014)

Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer
por: Chien, A. Jo, et al.
Publicado: (2012)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study
por: Haque, Reina, et al.
Publicado: (2017)

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
por: Honkanen, Tiia J., et al.
Publicado: (2021)

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022)

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
por: DeMichele, Angela, et al.
Publicado: (2021)

Role of hormonal risk factors in HER2-positive breast carcinomas
por: Balsari, A, et al.
Publicado: (2003)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
por: Law, Jeanna Wallenta, et al.
Publicado: (2022)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
por: Miller, Kathy, et al.
Publicado: (2016)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
por: Groen, Emma J., et al.
Publicado: (2021)

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term
por: Jankowitz, Rachel C, et al.
Publicado: (2012)

Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
por: Brufsky, Adam M
Publicado: (2014)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2011)

Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
por: Rugo, Hope S., et al.
Publicado: (2022)

Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents
por: Meyer, Nicole, et al.
Publicado: (2014)

Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016
por: Spanggaard, M., et al.
Publicado: (2022)

Treatment of HR+/HER2− breast cancer in urban mainland China: results from the CancerMPact Survey 2019
por: Murali, Bhavna, et al.
Publicado: (2022)

HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010
por: Malmgren, Judith A., et al.
Publicado: (2017)

P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2− Metastatic Breast Cancer—A Podcast
por: Brufsky, Adam, et al.
Publicado: (2023)

Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
por: Palm, Christiane, et al.
Publicado: (2023)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem, David D, et al.
Publicado: (2014)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sok3at64t0a7m1hpi0533b51kn